Drug-coated balloon outcomes in contemporary PCI: exploratory analysis by drug class and device

Introduction and objectives:To explore potential differences by drug class and device among contemporary coronary drug-coated balloons (DCBs).Methods: We conducted a national, 4-center, observational, retrospective study including all-comer patients undergoing DCB-based percutaneous coronary intervention between January 2023 and December 2024.Patients treated with more than 1 DCB brand were excluded.Patients were followed up for 1 year.The primary endpoint was target lesion failure (TLF), defined as a composite of cardiac death, target vessel-related myocardial infarction (TVMI), and clinically driven target lesion revascularization (TLR).To assess drug-and device-level effects, inverse probability of treatment weighting based on propensity scores was applied, and outcomes were analyzed using Cox proportional hazards models with clustering at the patient level.Results: A total of 1018 patients (1359 lesions) were included.At 1 year, TLF rates were similar between paclitaxel-and sirolimus-coated balloons (6.2% vs 4.6%; P = .204),with no significant difference after adjustment (HR, 1.22; 95%CI, 0.71-2.10;P = .474).Among paclitaxel-coated balloons, no significant differences in TLF were observed across the 3 devices.In contrast, among sirolimus-coated balloons, treatment with a microreservoir-based balloon was associated with a lower observed risk of TLF compared with a nanoparticle-based balloon (HR, 0.17; 95%CI, 0.05-0.58;P = .004).Conclusions: In this real-world multicenter study, paclitaxel-and sirolimus-coated balloons showed comparable 1-year outcomes.While paclitaxel devices demonstrated consistent performance across platforms, outcomes differed among sirolimus-coated balloons.The device-level findings should be considered exploratory and hypothesis-generating because of the limited number of events and the residual risk of confounding.

Authors

Institutions

Publication Details

Journal
REC interventional cardiology (English Edition)
Published
2026-11-12
DOI
https://doi.org/10.24875/recice.m26000628
Primary Topic
Coronary Interventions and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Drug-coated balloon outcomes in contemporary PCI: exploratory analysis by drug class and device

Hugo Vinhas, David Neves, Daniel Faria, Ana Esteves et al.
REC interventional cardiology (English Edition)
Coronary Interventions and Diagnostics
article

Drug-coated balloon outcomes in contemporary PCI: exploratory analysis by drug class and device

Hugo Vinhas, David Neves, Daniel Faria, Ana Esteves, and Francisco Soares, Lucas Hamann
article en

Abstract

Introduction and objectives:To explore potential differences by drug class and device among contemporary coronary drug-coated balloons (DCBs).Methods: We conducted a national, 4-center, observational, retrospective study including all-comer patients undergoing DCB-based percutaneous coronary intervention between January 2023 and December 2024.Patients treated with more than 1 DCB brand were excluded.Patients were followed up for 1 year.The primary endpoint was target lesion failure (TLF), defined as a composite of cardiac death, target vessel-related myocardial infarction (TVMI), and clinically driven target lesion revascularization (TLR).To assess drug-and device-level effects, inverse probability of treatment weighting based on propensity scores was applied, and outcomes were analyzed using Cox proportional hazards models with clustering at the patient level.Results: A total of 1018 patients (1359 lesions) were included.At 1 year, TLF rates were similar between paclitaxel-and sirolimus-coated balloons (6.2% vs 4.6%; P = .204),with no significant difference after adjustment (HR, 1.22; 95%CI, 0.71-2.10;P = .474).Among paclitaxel-coated balloons, no significant differences in TLF were observed across the 3 devices.In contrast, among sirolimus-coated balloons, treatment with a microreservoir-based balloon was associated with a lower observed risk of TLF compared with a nanoparticle-based balloon (HR, 0.17; 95%CI, 0.05-0.58;P = .004).Conclusions: In this real-world multicenter study, paclitaxel-and sirolimus-coated balloons showed comparable 1-year outcomes.While paclitaxel devices demonstrated consistent performance across platforms, outcomes differed among sirolimus-coated balloons.The device-level findings should be considered exploratory and hypothesis-generating because of the limited number of events and the residual risk of confounding.

REC interventional cardiology (English Edition)
Hospital de Faro EPE (PT), Hospital do Espírito Santo (PT), Hospital de São Bernardo (PT), Hospital de Santo André (PT), Unidade Local de Saúde da Arrábida (PT), Unidade Local de Saúde do Algarve (PT), Unidade Local de Saúde da Região de Leiria (PT), Unidade Local de Saúde do Alentejo Central (PT)
Good health and well-being
Coronary Interventions and Diagnostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon